Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amarin Corporation Plc (AMRN)
NASDAQ:AMRN
AMRN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.43 - $1.36
Previous CloseN/A
Volume726.09K
Average Volume (3M)1.12M
Market Cap
$249.72M
Enterprise Value-$40.29M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Feb 26, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding411,338,130
10 Day Avg. Volume1,090,488
30 Day Avg. Volume1,121,487
Standard Deviation0.23
R-Squared0.17
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.04
Price to Cash Flow (P/CF)-26.50
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.24
Enterprise Value/Ebitda1.04
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
---
Amarin News
PremiumCompany Announcements
Amarin Appoints Peter Fishman as New CFO
PremiumCompany Announcements
Amarin Corporation: Q3 Highlights and Future Outlook
---
Bulls Say, Bears Say
Bulls Say
Financial ManagementAmarin's tighter OpEx management with ~$43M in 2Q24 (~24% Y/Y reduction vs. 2Q23) and achieving ~$50M OpEx savings on an annualized basis since July 2023, exceeding their prior goal of ~$40M in OpEx savings.
Market ExpansionCommercial launch progress for Vascepa in China in the CV risk reduction indication via partner Eddingpharm could drive future growth.
Patent ProtectionEU patent protection extends exclusivity to 2039, which could enhance the stock's value.
Bears Say
Competition And Pricing PressureUS Vascepa still faces growing competition and pricing pressure from at least 8 generics, compressing its gross margins.
Loss Of Exclusive AccountsA large US national pharmacy benefit manager informed Amarin that it will no longer cover Vascepa as the exclusive icosapent ethyl product for its commercial national formularies, affecting a significant portion of the US Vascepa business.
Market Access ChallengesVazkepa's EU launch remains slower than expected due to continued market access challenges, which is an overhang on the stock.
---
Ownership Overview
0.44% Insiders
0.10% Mutual Funds
12.54% Other Institutional Investors
86.71% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AMRN FAQ
What was Amarin Corporation Plc’s price range in the past 12 months?
Amarin Corporation Plc lowest stock price was $0.43 and its highest was $1.36 in the past 12 months.
What is Amarin Corporation Plc’s market cap?
Amarin Corporation Plc’s market cap is $249.72M.
When is Amarin Corporation Plc’s upcoming earnings report date?
Amarin Corporation Plc’s upcoming earnings report date is Feb 26, 2025 which is in 5 days.
How were Amarin Corporation Plc’s earnings last quarter?
Amarin Corporation Plc released its earnings results on Oct 30, 2024. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.056 by -$0.004.
Is Amarin Corporation Plc overvalued?
According to Wall Street analysts Amarin Corporation Plc’s price is currently Overvalued.
Does Amarin Corporation Plc pay dividends?
Amarin Corporation Plc does not currently pay dividends.
What is Amarin Corporation Plc’s EPS estimate?
Amarin Corporation Plc’s EPS estimate is -0.05.
How many shares outstanding does Amarin Corporation Plc have?
Amarin Corporation Plc has 411,338,130 shares outstanding.
What happened to Amarin Corporation Plc’s price movement after its last earnings report?
Amarin Corporation Plc reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.056. Following the earnings report the stock price went down -3.333%.
Which hedge fund is a major shareholder of Amarin Corporation Plc?
Currently, no hedge funds are holding shares in AMRN
---
Amarin Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
AMRN Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.15%
12-Months-Change
Fundamentals
Return on Equity
-7.31%
Trailing 12-Months
Asset Growth
-10.54%
Trailing 12-Months
Company Description
Amarin Corporation Plc
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.
---
AMRN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted the potential for growth in Europe and other global markets but was overshadowed by significant declines in U.S. revenue and gross margins, increased net loss, and ongoing pricing pressures due to generic competition.Read More>---
AMRN Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering AMRN
1 Year
1 Year Success Rate
11/12 ratings generated profit
1 Year Average Return
+30.43%
reiterated a sell rating 7 months ago
Copying Paul Choi's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +30.43% per trade.
---